A prospective class action lawsuit has been filed against Boehringer Ingelheim Pharmaceutical Inc., alleging the Big Pharma company made false and misleading statements regarding its Combivent Respimat asthma inhaler.

The 24-page federal lawsuit in Connecticut accuses the international company of conducting “an extensive, widespread, comprehensive and uniform nationwide marketing campaign” that misrepresented the dosage of its Combivent inhalers. It claims the company offered metered-dose inhalers that were supposed to provide a set number of constant puffs, but which fell far short.